Boston Scientific Corporation (NYSE:BSX) agreed to acquire Bolt Medical, Inc., the developer of an intravascular lithotripsy ...

A study has revealed a significant link between a common pregnancy complication and early heart disease in women. The study ...

ANSWER: Whether stents are beneficial in people with stable coronary artery disease remains somewhat controversial. Although ...

Trientine hydrochloride is under clinical development by Innolife and currently in Phase II for Coronary Artery Disease (CAD) (Ischemic Heart Disease).

While genetics play a role in heart disease risk, lifestyle modifications can significantly influence outcomes. Individuals ...

A discussion with Campbell Rogers, MD, regarding advances in AI technology for prevention and management of coronary artery disease.

The company is trying to develop a one-time treatment for forms of heart disease that afflict more than 1 million people in ...

PR-15 is under clinical development by advanceCor and currently in Phase II for Coronary Artery Disease (CAD) (Ischemic Heart Disease).

Boston Scientific (BSX) announced on Wednesday the acquisition of the ~74% stake in Bolt Medical that the medical devices ...

CathWorks has completed the enrolment for a randomised controlled trial (RCT), evaluating the FFRangio system in diagnosing ...

Boston Scientific (BSX) announced it has entered into a definitive agreement to acquire Bolt Medical, the developer of an intravascular ...